06/03/2026 | Press release | Distributed by Public on 06/03/2026 05:00
| Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
On June 2, 2026, Viridian Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") at which holders of the Company's common stock as of the close of business on April 7, 2026 (the "Record Date") were entitled to vote. As of the close of business on the Record Date, 103,071,889 shares of the Company's common stock were issued and outstanding.
At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved. The final voting results are set forth below:
1. Election of the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders:
| For | Withheld | Broker Non-Votes | ||||||||||
|
Tomas Kiselak |
72,363,500 | 14,475,646 | 6,733,104 | |||||||||
|
Jennifer K. Moses |
86,378,842 | 460,304 | 6,733,104 | |||||||||
2. Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:
|
For |
Against |
Abstentions |
Broker Non-Votes |
|||
| 92,866,008 | 512,582 | 193,660 | - |
3. Approval, on an advisory basis, of the compensation of the Company's named executive officers:
|
For |
Against |
Abstentions |
Broker Non-Votes |
|||
| 83,512,086 | 3,113,724 | 213,336 | 6,733,104 |
4. Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company's named executive officers:
|
1 Year |
2 Years |
3 Years |
Abstain |
|||
| 86,084,347 | 29,762 | 517,682 | 207,355 |
As a result of the foregoing vote, the Company's Board of Directors has determined that the Company will conduct a non-binding advisory vote on the compensation of the Company's named executive officers every year.